Mutual antagonism between IP3RII and miRNA-133a regulates calcium signals and cardiac hypertrophy.

Babraham Institute, Babraham, Cambridge CB22 3AT, England, UK.
The Journal of Cell Biology (Impact Factor: 9.69). 11/2012; DOI: 10.1083/jcb.201111095
Source: PubMed

ABSTRACT Inositol 1,4,5'-triphosphate receptor II (IP(3)RII) calcium channel expression is increased in both hypertrophic failing human myocardium and experimentally induced models of the disease. The ectopic calcium released from these receptors induces pro-hypertrophic gene expression and may promote arrhythmias. Here, we show that IP(3)RII expression was constitutively restrained by the muscle-specific miRNA, miR-133a. During the hypertrophic response to pressure overload or neurohormonal stimuli, miR-133a down-regulation permitted IP(3)RII levels to increase, instigating pro-hypertrophic calcium signaling and concomitant pathological remodeling. Using a combination of in vivo and in vitro approaches, we demonstrated that IP(3)-induced calcium release (IICR) initiated the hypertrophy-associated decrease in miR-133a. In this manner, hypertrophic stimuli that engage IICR set a feed-forward mechanism in motion whereby IICR decreased miR-133a expression, further augmenting IP(3)RII levels and therefore pro-hypertrophic calcium release. Consequently, IICR can be considered as both an initiating event and a driving force for pathological remodeling.

Download full-text


Available from: Chihiro Hisatsune, Jun 20, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac disorders are the main cause of mortality in autosomal-dominant polycystic kidney disease (ADPKD). However, how mutated polycystins predispose patients with ADPKD to cardiac pathologies before development of renal dysfunction is unknown. We investigate the effect of decreased levels of polycystin 2 (PC2), a calcium channel that interacts with the ryanodine receptor, on myocardial function. We hypothesize that heterozygous PC2 mice (Pkd2(+/-)) undergo cardiac remodeling as a result of changes in calcium handling, separate from renal complications. We found that Pkd2(+/-) cardiomyocytes have altered calcium handling, independent of desensitized calcium-contraction coupling. Paradoxically, in Pkd2(+/-) mice, protein kinase A (PKA) phosphorylation of phospholamban (PLB) was decreased, whereas PKA phosphorylation of troponin I was increased, explaining the decoupling between calcium signaling and contractility. In silico modeling supported this relationship. Echocardiography measurements showed that Pkd2(+/-) mice have increased left ventricular ejection fraction after stimulation with isoproterenol (ISO), a β-adrenergic receptor (βAR) agonist. Blockers of βAR-1 and βAR-2 inhibited the ISO response in Pkd2(+/-) mice, suggesting that the dephosphorylated state of PLB is primarily by βAR-2 signaling. Importantly, the Pkd2(+/-) mice were normotensive and had no evidence of renal cysts. Our results showed that decreased PC2 levels shifted the βAR pathway balance and changed expression of calcium handling proteins, which resulted in altered cardiac contractility. We propose that PC2 levels in the heart may directly contribute to cardiac remodeling in patients with ADPKD in the absence of renal dysfunction.
    Proceedings of the National Academy of Sciences 11/2014; 108(2). DOI:10.1073/pnas.1415933111 · 9.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The type III isoform of the inositol 1,4,5-trisphosphate receptor (InsP3R3) is apically localized and triggers Ca2+ waves and secretion in a number of polarized epithelia. However, nothing is known about epigenetic regulation of this InsP3R isoform. We investigated miRNA regulation of InsP3R3 in primary bile duct epithelia (cholangiocytes) and in the H69 cholangiocyte cell line, because the role of InsP3R3 in cholangiocyte Ca2+ signaling and secretion is well established and because loss of InsP3R3 from cholangiocytes is responsible for the impairment in bile secretion that occurs in a number of liver diseases. Analysis of the 3&(prime)-UTR of human InsP3R3 mRNA revealed two highly conserved binding sites for miR-506. Transfection of miR-506 mimics into cell lines expressing InsP3R3-3&(prime)UTR-luciferase led to decreased reporter activity, while co-transfection with miR-506 inhibitors led to enhanced activity. Reporter activity was abrogated in isolated mutant proximal or distal miR-506 constructs in miR-506 transfected HEK293 cells. InsP3R3 protein levels were decreased by miR-506 mimics and increased by inhibitors, and InsP3R3expression was markedly decreased in H69 cells stably transfected with miR506 relative to control cells. miR506-H69 cells exhibited a fibrotic signature. In situ hybridization revealed elevated miR506 expression in vivo in human diseased cholangiocytes. Histamine-induced, InsP3-mediated Ca2+ signals were decreased by 50% in stable-miR-506 cells compared to controls. Finally, InsP3R3-mediated fluid secretion was significantly decreased in isolated bile duct units (IBDU) transfected with miR-506, relative to control IBDU. Together, these data identify miR-506 as a regulator of InsP3R3 expression and of InsP3R3-mediated Ca2+ signaling and secretion.
    Journal of Biological Chemistry 11/2014; 290(1). DOI:10.1074/jbc.M114.587030 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ischemic heart disease is a leading cause of morbidity and mortality.•MicroRNAs regulate gene expression by translational inhibition and degradation of target mRNAs.•Ischemic heart disease changes microRNA expression profiles.•MicroRNAs provide sensitive biomarkers and novel therapeutic targets of ischemic heart disease.
    Drug Discovery Today 10/2014; 20(2). DOI:10.1016/j.drudis.2014.10.004 · 5.96 Impact Factor